Disc Medicine (NASDAQ:IRON) Trading Down 40% – What’s Next?

Disc Medicine, Inc. (NASDAQ:IRON) shares fell 40% during trading on Friday . The company traded as low as $56.53 and last traded at $42.9990. 340,661 shares were traded during mid-day trading, a decline of 30% from the average session volume of 483,645 shares. The stock had previously closed at $71.65.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IRON shares. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Morgan Stanley reaffirmed an “overweight” rating and issued a $120.00 price objective on shares of Disc Medicine in a report on Thursday, January 8th. Truist Financial lifted their target price on Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, November 10th. National Bank Financial set a $153.00 price target on shares of Disc Medicine in a research note on Friday, October 17th. Finally, Wedbush reiterated an “outperform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $119.45.

Disc Medicine Trading Down 21.8%

The firm’s 50-day simple moving average is $80.40 and its 200 day simple moving average is $75.07. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -10.47 and a beta of 0.88.

Insiders Place Their Bets

In other Disc Medicine news, CEO John D. Quisel sold 40,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $93.05, for a total transaction of $3,722,000.00. Following the sale, the chief executive officer owned 171,828 shares of the company’s stock, valued at approximately $15,988,595.40. The trade was a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin Bitterman sold 754 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $91.47, for a total value of $68,968.38. Following the completion of the transaction, the director owned 14,013 shares of the company’s stock, valued at $1,281,769.11. The trade was a 5.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 245,470 shares of company stock valued at $22,425,170 in the last quarter. Corporate insiders own 3.64% of the company’s stock.

Hedge Funds Weigh In On Disc Medicine

Institutional investors and hedge funds have recently bought and sold shares of the company. Arizona State Retirement System grew its holdings in shares of Disc Medicine by 1.8% during the third quarter. Arizona State Retirement System now owns 6,654 shares of the company’s stock worth $440,000 after purchasing an additional 120 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Disc Medicine by 2.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,094 shares of the company’s stock valued at $469,000 after acquiring an additional 138 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Disc Medicine by 8.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after purchasing an additional 206 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Disc Medicine by 3.3% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after purchasing an additional 215 shares during the last quarter. Finally, Avanza Fonder AB increased its holdings in Disc Medicine by 14.1% in the fourth quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock valued at $151,000 after purchasing an additional 235 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.